Literature DB >> 7807193

Drug resistance in brain tumors.

L G Feun1, N Savaraj, H J Landy.   

Abstract

Resistance to chemotherapy in brain tumors is complex and may involve multiple mechanisms. For commonly used drugs, such as nitrosoureas and platinum compounds, major mechanisms may involve increaded DNA repair or removal of the drug-DNA adducts. For water soluble nitrosoureas and also for platinum compounds, other mechanisms, such as alteration in drug transport, may be important. Another major mechanism may involve glutathione and glutathione-S-transferase pathways. For vinca alkaloids and epipodophyllotoxins p-glycoprotein mediated MDR appears to be the major feature in drug resistance. In addition, alteration of tubulin and topoisomerase II have been described in resistance to vinca alkaloids and epipodophyllotoxins respectively. Recently, increased multidrug resistance associated protein gene expression has been found in glioma cells and brain tumor samples; its clinical significance requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7807193     DOI: 10.1007/bf01052726

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  89 in total

1.  Human tumor cell strains defective in the repair of alkylation damage.

Authors:  R S Day; C H Ziolkowski; D A Scudiero; S A Meyer; M R Mattern
Journal:  Carcinogenesis       Date:  1980-01       Impact factor: 4.944

2.  DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.

Authors:  E Sariban; K W Kohn; C Zlotogorski; G Laurent; M D'Incalci; R Day; B H Smith; P L Kornblith; L C Erickson
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

3.  Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms.

Authors:  B D Sklansky; R S Mann-Kaplan; A F Reynolds; M L Rosenblum; M D Walker
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

Review 4.  Antineoplastic drug resistance in brain tumors.

Authors:  P C Phillips
Journal:  Neurol Clin       Date:  1991-05       Impact factor: 3.806

5.  Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.

Authors:  T Lee; D Roberts
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

6.  In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).

Authors:  J M Onoda; K K Nelson; J D Taylor; K V Honn
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

7.  The mechanism and overcoming of resistance in ACNU-resistant sublines of C6 and 9L rat glioma.

Authors:  T Yoshida; K Shimizu; Y Ushio; T Hayakawa; H Mogami; Y Sakamoto
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

8.  Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

Authors:  U Tirelli; M D'Incalci; R Canetta; S Tumolo; G Franchin; A Veronesi; E Galligioni; M G Trovò; C Rossi; E Grigoletto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

9.  Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas.

Authors:  D A Scudiero; S A Meyer; B E Clatterbuck; M R Mattern; C H Ziolkowski; R S Day
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

10.  Cisplatin therapy in recurrent childhood brain tumors.

Authors:  A B Khan; B J D'Souza; M D Wharam; L A Champion; L F Sinks; S Y Woo; D C McCullough; B G Leventhal
Journal:  Cancer Treat Rep       Date:  1982-12
View more
  19 in total

1.  Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.

Authors:  Carolyn A Kitchens; Peter R McDonald; Tong Ying Shun; Ian F Pollack; John S Lazo
Journal:  J Pharmacol Exp Ther       Date:  2011-08-31       Impact factor: 4.030

2.  CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.

Authors:  G Xi; E Hayes; R Lewis; S Ichi; B Mania-Farnell; K Shim; T Takao; E Allender; C S Mayanil; T Tomita
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

3.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.

Authors:  M Nagane; A Levitzki; A Gazit; W K Cavenee; H J Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.

Authors:  H Roche; H Cure; A Adenis; P Fargeot; C Terret; M A Lentz; J C Madelmont; P Fumoleau; A Hanausk; P Chollet
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

5.  Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results.

Authors:  Amr Amin; Hosna Moustafa; Ebaa Ahmed; Mohamed El-Toukhy
Journal:  J Neurooncol       Date:  2011-09-13       Impact factor: 4.130

Review 6.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

7.  Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line.

Authors:  D Amendola; M De Salvo; R Marchese; C Verga Falzacappa; A Stigliano; E Carico; E Brunetti; M Moscarini; B Bucci
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

8.  Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.

Authors:  B C Liang
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

Review 9.  Cellular immunotherapy for pediatric solid tumors.

Authors:  Meenakshi Hegde; Alexander J Moll; Tiara T Byrd; Chrystal U Louis; Nabil Ahmed
Journal:  Cytotherapy       Date:  2014-07-28       Impact factor: 5.414

10.  Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

Authors:  T Abe; T Mori; Y Wakabayashi; M Nakagawa; S P Cole; K Koike; M Kuwano; S Hori
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.